Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Depreciation & Amortization (CF) (2016 - 2025)

Regenxbio (RGNX) has 11 years of Depreciation & Amortization (CF) data on record, last reported at $3.9 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 3.47% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $15.6 million, down 3.61%, while the annual FY2025 figure was $15.6 million, 3.61% down from the prior year.
  • Depreciation & Amortization (CF) reached $3.9 million in Q4 2025 per RGNX's latest filing, roughly flat from $3.9 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $4.4 million in Q2 2023 and bottomed at $1.9 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $3.6 million, with a median of $3.9 million recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 67.8% in 2023, then dropped 9.4% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.6 million in 2021, then soared by 58.33% to $4.1 million in 2022, then increased by 5.07% to $4.3 million in 2023, then decreased by 7.54% to $4.0 million in 2024, then fell by 3.47% to $3.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $3.9 million in Q4 2025, $3.9 million in Q3 2025, and $3.9 million in Q2 2025.